NYSE Arca · MAIA
MAIA Biotechnology, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MAIA: Nov 6, 2026
MAIA Biotechnology, Inc. Common Stock is estimated to report earnings on 11/06/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.13. The reported EPS for the same quarter last year was $-0.27.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Dec 2026 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Mar 2027 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Jun 2027 | $-0.15 | $-0.15 | $-0.15 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews- RTTNews · Oct 7, 12:04 PM EDTMAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65%(RTTNews) – MAIA Biotechnology, Inc. (MAIA), a clinical-stage biopharmaceutical company focused on targeted cancer immunotherapies, said it has reached an enrollment milestone of 150 patients treated with ateganosine sequenced with an immune checkpoint inhibitor in ongoing Phase
- RTTNews · Sep 24, 5:24 AM EDTMAIA Broadens Phase 3 Lung Cancer Study Footprint Across Europe(RTTNews) – MAIA Biotechnology, Inc. (MAIA) has expanded its pivotal Phase 3 THIO-104 trial into Spain and Portugal after receiving regulatory clearance from health authorities in both countries, marking another step toward a planned interim survival analysis in 2027.
- RTTNews · Sep 22, 3:46 PM EDTMAIA Reaches Enrollment Milestone Of 65 In Phase 3 THIO-104 For Ateganosine In Lung Cancer(RTTNews) – MAIA Biotechnology Inc. (MAIA), a clinical-stage biopharmaceutical company, on Tuesday announced reaching a target enrollment of 65 patients in the Phase 3 THIO-104 trial for Ateganosine as a third-line therapy in advanced non-small cell lung cancer (NSCLC).
- RTTNews · Sep 16, 2:57 PM EDTBiotech Stocks See Fresh Catalysts: Tempest, DataMEDS, NeurAxis & MAIA(RTTNews) – Biotech stocks were in focus Wednesday following a series of company updates, including Tempest Therapeutics' new in vivo CAR-T licensing deal, DataMEDS AI's Helomics acquisition, expanded coverage for NeurAxis' PENFS therapy and MAIA Biotechnology's first U.S. patien
- RTTNews · Sep 16, 11:36 AM EDTMAIA Doses First U.S. Patient In Phase 2 THIO-101 Trial For Advanced Non-Small Cell Lung Cancer(RTTNews) – MAIA Biotechnology, Inc. (MAIA) has dosed the first U.S. patient in its ongoing Phase 2 THIO-101 clinical trial evaluating Ateganosine, the company's telomere-targeting lead candidate, in third-line non-small cell lung cancer.
- RTTNews · Sep 16, 3:54 AM EDTMAIA Biotechnology Board Member, CEO Buys Shares Amid Phase 3 NSCLC Studies(RTTNews) – MAIA Biotechnology, Inc. (MAIA), a clinical-stage immune oncology company, announced insider buying activity as board member Ramiro Guerrero and founder and CEO Vlad Vitoc increased their ownership stakes.
- RTTNews · Sep 16, 3:54 AM EDTMAIA Biotechnology Board Member, CEO Buy Shares Amid Phase 3 NSCLC Studies(RTTNews) – MAIA Biotechnology, Inc. (MAIA), a clinical-stage immune oncology company, announced insider buying activity as board member Ramiro Guerrero and founder and CEO Vlad Vitoc increased their ownership stakes.
- RTTNews · Sep 10, 8:45 AM EDTMAIA Biotechnology Presents Ateganosine, Next-Generation Drug Data At IRT 2026(RTTNews) – MAIA Biotechnology, Inc. (MAIA) announced that it presented oral and poster data highlighting its next-generation telomere-targeting cancer therapies at the XXVI International Round Table on Nucleosides, Nucleotides and Nucleic Acids (IRT 2026) held in Barcelona, Spai
- RTTNews · Sep 1, 10:40 PM EDT6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More(RTTNews) – Today's after-hours gainers in the healthcare sector included Universe Pharmaceuticals, which drew attention after disclosing multiple Schedule 13G filings; bioAffinity Technologies, which is exploring a new use for its CyPath Lung test in monitoring lung cancer patie
- RTTNews · Jul 10, 12:10 PM EDTWeekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal(RTTNews) – This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech and pharmaceutical sectors.
- RTTNews · Jul 8, 12:18 PM EDTMAIA Reports Increased Disease Control Rate From Phase 2 THIO-101 For Ateganosine In Lung Cancer(RTTNews) – MAIA Biotechnology Inc. (MAIA), a clinical-stage biopharmaceutical company, on Wednesday released encouraging efficacy data from the Part C expansion of the Phase 2 THIO-101 trial for Ateganosine in treating non-small cell lung cancer.
- RTTNews · Jun 26, 8:06 AM EDTMAIA Completes International Enrollment In Phase 2 THIO-101 Part C For Ateganosine In Lung Cancer(RTTNews) – MAIA Biotechnology Inc. (MAIA), a clinical-stage biopharmaceutical company, on Thursday announced completion of international enrollment in the Part C of Phase 2 THIO-101 expansion trial for Ateganosine in treating advanced non-small cell lung cancer (NSCLC).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for MAIA Biotechnology, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.